Loading...
Docoh

Karuna Therapeutics (KRTX)

Utility
Compounds and Methods of Deuterated Xanomeline for Treating Neurological Disorders
12 May 22
Provided herein are compounds of Formula I and/or salts thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22 and R23 are independently chosen from H and D.
Dennis BENNETT, Giorgio ATTARDO, Clifford SCHLECHT
Filed: 21 Feb 20
Utility
Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
17 Jun 21
Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
Filed: 7 Jan 21
Utility
Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
27 May 21
Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT
Filed: 4 Feb 21
Utility
Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
20 May 21
Provided herein is a method of treating schizophrenia or a disease related to schizophrenia in a patient in need thereof.
Stephen BRANNAN, Andrew MILLER
Filed: 17 Nov 20
Utility
Xanomeline Derivatives and Methods for Treating Neurological Disorders
20 May 21
James A. MONN, Clifford Adam SCHLECHT, Dennis A. BENNETT, Giorgio ATTARDO
Filed: 16 Nov 20
Utility
Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
2 Mar 21
Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof, and a plurality of trospium beads having a core comprising a salt of trospium.
Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
Filed: 27 Sep 19
Utility
Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation
23 Feb 21
Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
Filed: 21 May 20
Utility
Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
16 Sep 20
Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT
Filed: 20 May 20
Utility
Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
1 Apr 20
Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT
Filed: 26 Sep 19
  • 1
Patents are sorted by USPTO publication date, most recent first